Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

Completed · Phase 2 · Has a placebo group

Conditions studied: Opioid-related Disorders

In brief

The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.

Key facts

Study ID

NCT00637000

Run by

Indivior Inc.

People needed

38

Starts

2008-03-01

Expected to finish

2008-09-01

Last updated by the study team

2017-06-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must:
• Provide written informed consent.
• Have a Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of opioid dependence.
• Be male or female, 18 to 65 years of age, inclusive.
• If female, have a negative pregnancy test during screening and agree to use an acceptable method of birth control.

You may not qualify if…

• Subjects must not:
• Have participated in an experimental drug or device study within the last 30 days.
• Be currently (past 30 days from start of screening) engaged in opioid agonist, opioid partial agonist, or opioid antagonist treatment.
• If female, be breast feeding or lactating.
• Have any medical condition that in the opinion of the physician investigator would preclude the subject from completing the study.
• Have any clinically significant non-substance use psychiatric disorder (e.g., schizophrenia).
• Have current suicidal ideation.
• Have a Mini Mental Status Exam score less than 24.
• Have physical dependence on alcohol.
• Have physical dependence on sedative-hypnotics.
• Have active aphthous stomatitis.
• Have active oral herpes.
• Need on-going prescription medications that interact with the P450 3A4 (a member of the cytochrome P450 superfamily of enzymes) system.

Where it is running

• Johns Hopkins University School of Medicine — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.